MAHA Rejoices After White House Drops Controversial FDA Nomination

The Daily Caller
Original Story by The Daily Caller
November 18, 2026
MAHA Rejoices After White House Drops Controversial FDA Nomination

Gottlieb, the former FDA chief who later joined Pfizer’s board, is backing Heidi Overton for FDA commissioner, signaling a renewed sweep of ties between the agency and Big Pharma. His advocacy follows a history in which he publicly clashed with Kennedy Jr. yet now appears to influence Overton’s confirmation, a shift noted by multiple former Trump administration officials. Overton’s path to confirmation is complicated by her involvement in an executive-order policy on childhood vaccinations and the need to balance skepticism from MAHA critics with industry-friendly lawmakers. The dynamic underscores concerns about industry influence over regulatory leadership, even as Gottlieb and allies portray Overton as capable of bridging innovation and public health. Gottlieb has money tied to Pfizer, having received about $2.5 million since 2019, highlighting potential conflicts of interest as discussions unfold.

Dive Deeper:

  • Gottlieb, a former FDA commissioner who later joined Pfizer’s board, is actively supporting Heidi Overton’s bid to become FDA commissioner, according to two former Trump administration officials.

  • Overton’s nomination faces scrutiny because of her role in a Trump-era executive order on childhood vaccination schedules, creating a balancing act between anti-Big Pharma critics and industry-friendly senators.

  • Two factions recount Gottlieb’s involvement: one says he’s been a behind-the-scenes ally pushing Overton’s confirmation; another suggests his involvement was limited to a courtesy role without active prep sessions.

  • STAT News coverage, coauthored by Mark McClellan, portrays Overton as a trustworthy leader who could bridge strained institutions and accelerate medical innovation while strengthening the agency’s mission.

  • Grace Stuntz Graham, a deputy FDA official, has acted as Overton’s sherpa for the confirmation process, with past ties to Gottlieb’s aides on the Senate Health Committee—links that intensify scrutiny of regulatory capture concerns.

  • Gottlieb’s public history includes harsh criticism of Kennedy Jr.’s readiness to run HHS and concerns that Kennedy’s vaccine policy shifts could threaten pediatric vaccine programs, framing the current endorsement as a notable pivot.

  • McClellan’s own industry ties include board work at Johnson & Johnson and advisory roles connected to Blackstone’s Moderna investments, illustrating enduring industry access at high levels of medical policy discussion.

Latest News

Related Stories